Analysis of HLA-DRB1 alleles in Japanese patients with chronic myelogenous leukemia

American Journal of Hematology

Volumn 63, Issue 2, 2000, Pages 99-101

  Yasukawa, Masaki ^a   Ohminami, Hideki ^a   Kojima, Kensuke ^b   Inokuchi, Koiti ^c   Nishimura, Yasuharu ^d   Fujita, Shigeru ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b EHIME PREFECTURAL CENTRAL HOSPITAL   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

^d KUMAMOTO UNIVERSITY   (Japan)

Author keywords

bcr abl fusion protein; CD4+ T lymphocytes; Chronic myelogenous leukemia; Genetic association; HLA DRB1

Indexed keywords

ALLELE; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; GENETIC ASSOCIATION; HLA SYSTEM; HUMAN; JAPAN; PRIORITY JOURNAL;

EID: 0033971570     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1096-8652(200002)63:2<99::aid-ajh8>3.0.co;2-%23     Document Type: Article

References (10)

1. Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: Biologic significance and implications for the assessment of minimal residual disease. Blood 1998;92:3362-3367.
2. Cullis JO, Barret AJ, Goldman JM, Lechler RI. Binding of BCR/ABL junctional peptides to major histocompatibility complex (MHC) class I molecules: Studies in antigen-processing defective cell lines. Leukemia 1994;8:165-170.
3. Bocchia M, Korontsvit T, Xu Q. Mackinnon S, Yang SY, Sette A, Scheinberg DA. Specific human cellular immunity to ber-abl oncogene-derived peptides. Blood 1996;87:3587-3592.
4. Greco G, Fruci D, Accapezzato D, Barnaba V, Nisini R, Alimena G, Montefusco E, Vigneti E, Butler R, Tanigaki N, Tosi R. Two ber-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes. Leukemia 1996;10:693-699.
5. Buzyn A, Ostankovitch M, Zerbib A, Kemula M, Connan F, Varet B, Guillet J-G, Chopping J. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes. Eur J Immunol 1997;27: 2066-2072.
6. Cortes J, Fayad L, Kantarjian H, O'Brien S, Lee M-S, Talpaz M. Association of HLA phenotype and response to interferon-α in patients with chronic myelogenous leukemia. Leukemia 1998;12:455-462.
7. + T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood 1996;88:3522-3527.
8. Pawelec G, Max H, Halder T, Bruserud Ø, Merl A, da Silva P, Kalbacher H. BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. Blood 1996;88: 2118-2124.
9. + T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates. Blood 1997;90:290-297.
10. + cytotoxic T-cell clones specific for ber-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner. Blood 1998;92: 3355-3361.